The Association of Coagulation Factor V (Leiden) and Factor II (Prothrombin) Mutations with Stroke

Abstract

Background:Epidemiological studies indicate that over the past forty years, the stroke incidence rates has increased. Factors V and II mutations are established genetic-variant risk factors for venous thrombosis; however, their contribution to stroke is a controversial issue.Objectives:This study aimed to investigate the potential association of FV and FII mutations with stroke in an Iranian population.Patients and Methods:The study population consisted of 153 patients of different stroke subtypes (except cryptogenic strokes), admitted to Ghaem Hospital, Mashhad, Iran. The control group included 153 age- and sex-matched subjects without a history of cerebrovascular or neurologic diseases. Mutations of FV and FII were determined by using a TaqMan SNP Genotyping technique. The chi-square and Exact Fisher tests were used to analyze the baseline characteristics. Results were as follows: The calculated P-value for sex and diabetes mellitus were 0.907 and 1.000, respectively. The case and control groups were also matched in low density lipoprotein (P = 0.816), high density lipoprotein (P = 0.323), triglyceride (P = 0.846), and total cholesterol (P = 0.079).Results:Analysis of the FV showed that none of the study subjects were AA homozygous for this mutation and only 6 heterozygous subjects were detected in the case and control groups. Regarding FII variants, none of the study subjects were AG heterozygous and only 1 AA homozygous was detected in the control group.Conclusions:The prevalence of both FV and FII variants are population based. Iran is an ethnically diverse country. Therefore, for a comprehensive analysis of a potential association of FV and/or FII mutations with stroke among Iranian population, epidemiological studies could be conducted among different ethnic groups.

Factor V Leiden and prothrombin G20210A mutations and risk of vaso-occlusive complications in sickle cell disease: A meta-analysis through the lens of nephrology

“…DOI: 10.15171/npj.2019. 16. reductase (MTHFR) genes (7). FVL refers to the G1691A (Arg506Gln; rs6025) mutation in exon 10 of the factor V (FV) gene.…”

Factor V Leiden, Factor II, Protein C, Protein S, and Antithrombin and Ischemic Strokes in Young Adults: A Meta-Analysis

“…After duplicates were excluded, we assessed the titles and abstracts of the records and rejected articles that did not meet the inclusion criteria. At the end, there were 104 eligible studies in total—42 for FVL [ 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 ], 30 for prothrombin [ 15 , 17 , 18 , 19 , 21 , 22 , 23 , 24 , 27 , 28 , 31 , 32 , 33 , 34 , ...…”

Relationship between factor V leiden gene variant and risk of ischemic stroke: A case–control study

“…In this study, the prevalence of Factor V heterozygous genotype was 2.6% in cases and 1.3% in the control subjects. [ 11 ] Another study reported from Greece also failed to observe the statistically significant association between Factor V Leiden gene polymorphism and risk of IS. [ 12 ] A study published by Hamedani in 2013, failed to observe the evidence of an association between Factor V Leiden and either overall IS or the different subtypes of IS.…”